Incidence of death or BPD does not differ with expectant management versus active treatment for preterm infants with protocol-defined PDA.

A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm babies. Findings from the ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

The US Food and Drug Administration has cleared the smallest occlusion device to date for the treatment of symptomatic patent ductus arteriosus (PDA) in premature infants, device manufacturer Abbott ...

Background: Recent studies have demonstrated that platelet count (PLTc) and function have an important role in promoting spontaneous closure of the PDA in animal models. Aimto evaluate whether ...

The multicentre, randomised, double-blind, placebo-controlled Baby-OSCAR trial. Participants were 653 extremely preterm infants with a large patent ductus arteriosus (diameter, ≥ 1.5 mm). In the first ...

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...

Background Ibuprofen treatment of patent ductus arteriosus (PDA) has been shown to be as effective as indomethacin in small randomized controlled trials, with possibly fewer adverse effects. However, ...